Ebola Outbreak in the Democratic Republic of the Congo and Uganda: A Comprehensive Risk Assessment

Overview

On 15 May 2026, the Africa CDC reported an Ebola disease outbreak in the Ituri Province of the Democratic Republic of the Congo (DRC). The outbreak is attributed to the Bundibugyo virus (BDBV), a relatively rare but dangerous strain known for high case-fatality rates. Shortly afterward, both the World Health Organization (WHO) and Africa CDC declared public health emergencies at international and continental levels, responding to the crisis's complexity and potential reach.

Current Epidemiological Situation

Recent data as of 20 May 2026 from the World Health Organisation reveal that approximately 600 suspected cases have emerged, accompanied by 139 fatalities. Confirmed BDBV infections have arisen in 51 cases within the DRC's Ituri and North Kivu provinces, with two cases documented in Kampala, Uganda. There have been five confirmed deaths related to these cases—the developing situation's dynamic and fast-evolving nature warrants caution, with potential underreporting of incidents both in number and geographic scope.

Transmission of BDBV necessitates direct contact with the infected individual's blood or bodily fluids, or with contaminated materials. The virus can also spread through interaction with infected wildlife or consuming bushmeat.

Risk Assessment for the EU/EEA

Despite limited epidemiological details, the risk of BDBV infection for EU/EEA individuals in affected zones remains low, contingent upon adherence to precautionary advice. For most EU/EEA residents and travelers, exposure scenarios are improbable without direct engagement in high-risk activities or regions.

The primary transmission risk to the EU/EEA is posed by infected travelers. Historical context from the 2013-2016 West Africa Ebola epidemic—which saw minimal cases entering Europe—suggests similar rare importation is expected for this outbreak.

Thus, the secondary transmission probability and constant transmission chains within the EU/EEA are categorized as extremely low, as affected individuals would be rapidly isolated, and control measures would be executed efficiently.

Recommendations for Public Health Authorities

Public health officials in EU/EEA are urged to:

1. Elevate awareness for travelers and residents in impacted areas, and those returning.

2. Enhance healthcare personnel knowledge to identify potential BDBV cases in returning travelers, recognize clinical symptoms, and implement suitable infection controls.

3. Fortify testing capacities and review diagnostic protocols.

4. Provide comprehensive information for returning travelers to aid early detection and contain potential spread.

Exit screening strategies, focused on symptom checks in affected regions, are critical, although not foolproof, for minimizing the exportation of BDBV.

ECDC's Role

The European Centre for Disease Prevention and Control (ECDC) continues to monitor the outbreak closely, providing updates and coordinating expert deployments to reinforce public health responses. ECDC remains in collaboration with relevant agencies to ensure preparedness and effective management in the face of these and future health threats.

Conclusion

While the BDBV outbreak presents severe challenges in its originating regions, the broader risk to European territories remains minimal, contingent on current and proactive health measures. As the situation unfolds, continued vigilance and adherence to public health guidance will be paramount in safeguarding against widespread impact.